stockrowLatest quarter
Kodiak Sciences reported a diluted loss per share of −$1.05 for the latest quarter, compared with −$1.03 a year earlier. Its adjusted loss per share was −$1.05, compared with the consensus estimate of −$0.97.
Kodiak’s free cash flow was −$46.6 million for the quarter, compared with −$34.8 million a year earlier. The company is precommercial and has not generated product revenue since inception.
Kodiak is a clinical-stage biotechnology company developing medicines for diseases of the retina, the light-sensitive tissue at the back of the eye. Its lead investigational medicine, Zenkuda, is designed to block VEGF, a protein involved in retinal vascular disease. Kodiak is developing the eye-injected medicine for diabetic retinopathy, retinal vein occlusion and wet age-related macular degeneration. The company has funded operations primarily by issuing common stock and selling rights to future royalties.
| Q2 FY2026 | Q2 FY2025 | Change | |
|---|---|---|---|
| Diluted EPS | −$1.05 | −$1.03 | — |
| Free cash flow | −$46.6 million | −$34.8 million | — |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | −$1.05 | −$0.97 | Missed by 8.25% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
A transcript of Kodiak’s latest earnings call is not available for review.
Guidance
Management’s guidance is not available. Kodiak intends to file a biologics license application for Zenkuda in diabetic retinopathy, retinal vein occlusion and wet age-related macular degeneration.